{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifij7lyt6b4gh7ecq3zoxxi7ghbsu5eog6rx7bddokcrzuuvswyyq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mktr66hq4c42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/05/01/obesity-drugs-excluded-from-compounding-list-astrazeneca-setback/?utm_campaign=rss",
  "publishedAt": "2026-05-01T13:45:35.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions",
  "title": "STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more",
  "updatedAt": "2026-05-01T13:45:40.000Z"
}